Success Metrics

Clinical Success Rate
78.6%

Based on 11 completed trials

Completion Rate
79%(11/14)
Active Trials
0(0%)
Results Posted
55%(6 trials)
Terminated
3(17%)

Phase Distribution

Ph phase_3
2
11%
Ph phase_2
3
17%
Ph phase_4
8
44%
Ph not_applicable
2
11%

Phase Distribution

0

Early Stage

3

Mid Stage

10

Late Stage

Phase Distribution15 total trials
Phase 2Efficacy & side effects
3(20.0%)
Phase 3Large-scale testing
2(13.3%)
Phase 4Post-market surveillance
8(53.3%)
N/ANon-phased studies
2(13.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.3%

11 of 15 finished

Non-Completion Rate

26.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(11)
Terminated(4)
Other(3)

Detailed Status

Completed11
Terminated3
unknown3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
78.6%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (20.0%)
Phase 32 (13.3%)
Phase 48 (53.3%)
N/A2 (13.3%)

Trials by Status

withdrawn16%
terminated317%
unknown317%
completed1161%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT03832179Phase 4

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

Completed
NCT03984110Phase 4

One Year Trial Evaluating Safety of Ozurdex With Eylea

Completed
NCT05990829Phase 4

Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial

Unknown
NCT03908307Phase 4

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Completed
NCT02688309

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

Terminated
NCT03629210Phase 2

Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema

Withdrawn
NCT01471054Phase 2

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Terminated
NCT02684084Phase 4

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

Terminated
NCT02121197

Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.

Completed
NCT01613716Phase 4

Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)

Completed
NCT01243086Phase 2

OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab

Completed
NCT01231633Not Applicable

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Completed
NCT01449682Phase 3

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

Completed
NCT01892163Phase 3

Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone

Completed
NCT01701518Not Applicable

A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes

Unknown
NCT01827722Phase 4

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

Unknown
NCT02036424Phase 4

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

Completed
NCT01945892

Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18